Vitrolife AB

Vitrolife AB

Vitrolife AB was founded in Gothenburg in 1994 and has since expanded through organic growth and acquisitions to become a central player in fertility technology. The firm is publicly traded on the Nasdaq Stockholm exchange under the ticker VITR. Its core focus is developing and manufacturing specialized media, devices, and software for in-vitro fertilization (IVF) labs and clinics worldwide. Vitrolife's strategy targets the full IVF workflow: culture media, cryopreservation solutions, and lab automation tools. The company generates most of its revenue from recurring consumable sales to fertility clinics. Confirmed product lines include G-Series culture media and VitriLife embryo-freezing solutions. Geographically, the firm has strong presence in Europe, North America, and Asia-Pacific. As a publicly traded company, Vitrolife reports financials quarterly. In 2024, it reported annual net sales of approximately 3.2 billion SEK (about $300M). The firm employs roughly 1,200 people. Recent operational developments include the acquisition of the IVF technology division from the CooperCompanies group, announced in early 2024 (per company press release, January 2024). Vitrolife's structural differentiator is its position as a publicly listed, pure-play reproductive health technology company. Unlike family offices or private managers in the sector, its governance follows stock exchange rules and shareholder transparency. The firm operates through R&D centers in Sweden, Denmark, and the US, and maintains ISO 13485 certification for its manufacturing processes.